Small molecules, big impact: 20 years of targeted therapy in oncology
Philippe L Bedard1, David M Hyman2, Matthew S Davids3
1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Abstract:
The identification of molecular targets and the growing knowledge of their cellular functions have led to the development of small molecule inhibitors as a major therapeutic class for cancer treatment. Both multitargeted and highly selective kinase inhibitors are used for the treatment of advanced treatment-resistant cancers, and many have also achieved regulatory approval for early clinical settings as adjuvant therapies or as first-line options for recurrent or metastatic disease. Lessons learned from the development of these agents can accelerate the development of next-generation inhibitors to optimise the therapeutic index, overcome drug resistance, and establish combination therapies. The future of small molecule inhibitors is promising as there is the potential to investigate novel difficult-to-drug targets, to apply predictive non-clinical models to select promising drug candidates for human evaluation, and to use dynamic clinical trial interventions with liquid biopsies to deliver precision medicine.
Insights
Small molecule inhibitors are key cancer therapeutics, treating resistant and advanced cancers. Future research will optimize these drugs for better efficacy and personalized medicine approaches.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Small molecule inhibitors represent a significant therapeutic class in cancer treatment, driven by advances in identifying molecular targets and understanding cellular functions.
- Both multitargeted and selective kinase inhibitors are crucial for managing advanced, treatment-resistant cancers and are increasingly approved for early-stage and recurrent/metastatic disease settings.
Purpose of the Study:
- To review the current landscape of small molecule inhibitors in cancer therapy.
- To discuss lessons learned from inhibitor development to guide future research.
- To explore the potential of next-generation inhibitors and precision medicine strategies.
Main Methods:
- Review of existing literature on small molecule inhibitors in cancer treatment.
- Analysis of therapeutic applications, including adjuvant and first-line options.
- Discussion of strategies for overcoming drug resistance and optimizing therapeutic indices.
Main Results:
- Small molecule inhibitors are effective against advanced and resistant cancers.
- These agents are approved for various clinical settings, including adjuvant and first-line therapies.
- Lessons learned emphasize optimizing therapeutic index, overcoming resistance, and developing combination therapies.
Conclusions:
- The development of small molecule inhibitors has significantly advanced cancer treatment.
- Future directions include targeting novel, difficult-to-drug targets and utilizing predictive models.
- Precision medicine approaches, incorporating dynamic clinical trials and liquid biopsies, hold great promise for future cancer therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:15Drugs that Stabilize Microtubules
02:56Treatment Resistant Cancers